IceCure Medical (ICCM) Cash & Equivalents (2020 - 2026)

IceCure Medical (ICCM) has 7 years of Cash & Equivalents data on file, last reported at $8.1 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $8.1 million, up 34.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.1 million (up 34.35% YoY), and the FY2025 annual result was $8.9 million, up 17.62% from the prior year.
• Cash & Equivalents eased to $8.1 million in Q1 2026 per ICCM's latest filing, from $8.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $25.6 million in Q4 2022 and troughed at $3.0 million in Q2 2023.
• A 5-year average of $10.0 million and a median of $8.9 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents plunged 77.49% in 2023, then soared 247.51% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $25.6 million in 2022, then sank by 58.89% to $10.5 million in 2023, then dropped by 28.19% to $7.6 million in 2024, then rose by 17.62% to $8.9 million in 2025, then retreated by 8.79% to $8.1 million in 2026.
• Business Quant data shows ICCM's Cash & Equivalents at $8.1 million in Q1 2026, $8.9 million in Q4 2025, and $5.0 million in Q3 2025.